Home > Result Summaries: Compounds > Haemophilus influenzae Type b Vaccine Result Summaries: Haemophilus influenzae Type b Vaccine GSKStudy ID Phase Title Summary (Download) 104124 phase 4 Assess the safety & reactogenicity of GSK Biologicals Hib vaccine co-administered with Chinese local DTPw vaccine when compared to Chinese local DTPw vaccine administered alone, in healthy infants at 3,4 & 5 mths of age (0 citation(s)) 104297_2 phase 2 An open study for a 2-year period to confirm the safety and immunogenicity of the candidate malaria vaccine RTS,S/AS02A in Mozambican children aged 1 to 4 years at the time of first vaccine dose. (3 citation(s)) 106369_ phase 2 Safety and immunogenicity study of GSK Biologicals’ investigational vaccination regimen, when incorporated into an Expanded Program on Immunization (EPI) regimen that includes Tritanrix HepB/Hib, OPV, measles and yellow fever vaccination in infants (4 citation(s)) 106445_ phase 3 Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC with Priorix™, versus MenC-CRM197 vaccine with Hiberix™ & Priorix™ in toddlers primed with Hib but not MenC & to evaluate persistence up to 5y after vaccination. (5 citation(s)) 110808_ phase 3 Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A or Prevenar™ co-administered with Hiberix™ (10 citation(s)) 111188_ phase 3 Primary vaccination course in healthy children receiving the pneumococcal vaccine GSK 1024850A co-administered with Tritanrix-HepB/Hib at 6, 10 and 14 weeks of age. (2 citation(s)) 112899_1 phase 2 Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy infants (0 citation(s)) 112933_ phase 3 Booster vaccination with pneumococcal vaccine GSK1024850A or Prevenar™ co-administered with Hiberix™ in children primed with the same vaccines (4 citation(s)) 112957 phase 3 Phase III, partially double-blind study to evaluate consistency and immunogenicity of 3 lots of GSK Biologicals' Hib conjugate vaccine 208108 versus ActHIB and Pentacel at 2, 4, 6 and 15-18 months of age in healthy infants (0 citation(s)) 208108/059 Phase 4 A post-marketing surveillance study of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b (Hib) tetanus conjugate vaccine in 3,000 Filipino subjects. (0 citation(s)) 208108/084 Phase 3 An open study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' Haemophilus influenzae type b vaccine administered at 2, 4, 6 months to healthy infants over 2 months of age as a primary vaccination course (1 citation(s)) 208108/087 Phase 2 Phase 2 open randomized primary vaccination study to assess the immunogenicity and reactogenicity of GSK Bios Haemophilus influenzae type b conjugate vac admin with commercially available DTPw vac as compared to GSK Bios’ Hib admin mixed with GSK Bios’ DTPw vac in healthy infants (1 citation(s)) 208108/091 phase 2 Immunogenicity, safety and reactogenicity of GSK Biologicals’ Tritanrix™-HepB low thio/Hib2.5 Gödöllö compared to GSK Biologicals’ Tritanrix™-HepB/Hiberix™Gödöllö when administered as a 3-dose primary vaccination course to healthy infants (0 citation(s)) 208108-083 Phase 4 A phase IV, open, multicentric, post-marketing surveillance study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b vaccine (Hiberix™) in Korean subjects administered according to the Prescribing Information. (0 citation(s)) 208140/005p Phase 3 Immunogenicity and reactogenicity of GSK’s DTPa-HBV vaccine and GSK’s Hib vaccine, when administered simultaneously in 2 separate injections or in one single injection, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months (0 citation(s)) 208140/020 Phase 3 Immunogenicity & reactogenicity study of GSK’s DTPa-HBV & dtpa-HBV vaccines when administered with GSK’s Hib vaccine, either mixed and given in 1 single injection or given in 2 concomitant injections, as a booster vaccination at 15 to 22 months to healthy children, previously primed with a 3 doses of DTPa-HBV (0 citation(s)) 208140/032 Phase 4 Open clinical study of the immunogenicity and reactogenicity of SB Biologicals’ DTPa-HBV vaccine, when coadministered with SB Biologicals’ Hib vaccine in 2 concomitant injections into opposite limbs, as a primary vaccination course in healthy infants aged 2, 4 and 6 months, followed by a booster at 18 months (0 citation(s)) 208140/038 Phase 3 Immunogenicity and reactogenicity study of GSK’s DTPa HBV and Hib, either mixed or given in 2 concomitant injections, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months (0 citation(s)) 213501/018_1 phase 3 Study to evaluate immunogenicity, safety and reactogenicity of two different immunization regimens against hepatitis B, diphtheria, tetanus, pertussis and Haemophilus influenzae type b (Hib)diseases in healthy infants primed with a birth dose of GSK Bio’s hepatitis B (4 citation(s)) 213503/004 Phase 2/3 Immunogenicity and reactogenicity study of GSK’s combined diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, coadministered with GSK’s Haemophilus influenzae type b conjugate vaccine, either in 2 concomitant injections or mixed in one injection, given to healthy infants at 2, 4 and 6 months (1 citation(s)) 213503/005 Phase 3 Consistency study in terms of immunogenicity & reactogenicity of 2 lots of GSK’s DTPa-IPV vaccine coadministered with GSK’s Hib vaccine, either simultaneously in 2 separate injections or mixed in 1 single injection, as a primary vaccination course to healthy infants at 2, 4 and 6 months (0 citation(s)) 213503/013 Phase 2 Immunogenicity & reactogenicity study of coadministration of GSK’s DTPa-IPV vaccine & GSK’s Hib vaccine, either mixed & given in 1 single injection, or given in 2 concomitant injections, as a booster vaccination to healthy children, previously primed with a 3 dose primary vaccination course using same vaccine (0 citation(s)) 213503/026 Phase 3 Reactogenicity and immunogenicity study of GSK’s DTPa coadministered with GSK’s Hib in 2 concomitant injections or mixed and to GSK’s DTPa-IPV mixed with GSK’s Hib, administered as a booster to healthy children in their second year of life, previously primed with 3 doses of GSK’s DTPa-HBV-IPV (0 citation(s)) 217744/035 Phase 2 A booster vaccination study of one dose of GSK’s DTPa HBV IPV vaccine, coadministered with 2 formulations of GSK’s Hib conjugate vaccine, either mixed or injected in 2 concomitant injections, in healthy children who participated in Study 217744/011 (DTPa-HBV-IPV-011) or 217744/016 (DTPa-HBV-IPV-016) (0 citation(s)) 257049/026_2 phase 2 A study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ candidate malaria vaccine RTS,S/AS02A, administered intramuscularly according to a 0, 1 and 2 month vaccination schedule in toddlers and children aged 1 to 4 years (4 citation(s)) 347414/029 Phase 2 Multinational, randomised, controlled, open, phase 2 clinical study to evaluate the safety and immunogenicity of GSK Bios’ investigational vaccination regimen admin as a booster dose to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study (0 citation(s)) 347414/036 Phase 3 AA phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Bio’s investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study. (0 citation(s)) 371594/006 Phase 2 A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen, to healthy toddlers primed in study 371594/004. (0 citation(s)) 759346/009 phase 2 Study to evaluate immunogenicity, reactogenicity and safety of investigational vaccination regimen as compared to GSK Bio’s Hiberix vaccine, extemporaneously mixed with GSK Bio’s Tritanrix-HepB, when administered intramuscularly in infants at 6, 10 and 14 weeks of age (1 citation(s))
